Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R - Filippi, A.R.; Bar, J.; Chouaid, C.; Christoph, D.C.; Field, J.K.; Fietkau, R.; Garassino, M.C.; Garrido, P.; Haakensen, V.D.; Kao, S.; Markman, B.; McDonald, F.; et al. (ESMO Open, 2024)